<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24759703</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Coxsackievirus cloverleaf RNA containing a 5' triphosphate triggers an antiviral response via RIG-I activation.</ArticleTitle><Pagination><StartPage>e95927</StartPage><MedlinePgn>e95927</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e95927</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0095927</ELocationID><Abstract><AbstractText>Upon viral infections, pattern recognition receptors (PRRs) recognize pathogen-associated molecular patterns (PAMPs) and stimulate an antiviral state associated with the production of type I interferons (IFNs) and inflammatory markers. Type I IFNs play crucial roles in innate antiviral responses by inducing expression of interferon-stimulated genes and by activating components of the adaptive immune system. Although pegylated IFNs have been used to treat hepatitis B and C virus infections for decades, they exert substantial side effects that limit their use. Current efforts are directed toward the use of PRR agonists as an alternative approach to elicit host antiviral responses in a manner similar to that achieved in a natural infection. RIG-I is a cytosolic PRR that recognizes 5' triphosphate (5'ppp)-containing RNA ligands. Due to its ubiquitous expression profile, induction of the RIG-I pathway provides a promising platform for the development of novel antiviral agents and vaccine adjuvants. In this study, we investigated whether structured RNA elements in the genome of coxsackievirus B3 (CVB3), a picornavirus that is recognized by MDA5 during infection, could activate RIG-I when supplied with 5'ppp. We show here that a 5'ppp-containing cloverleaf (CL) RNA structure is a potent RIG-I inducer that elicits an extensive antiviral response that includes induction of classical interferon-stimulated genes, as well as type III IFNs and proinflammatory cytokines and chemokines. In addition, we show that prophylactic treatment with CVB3 CL provides protection against various viral infections including dengue virus, vesicular stomatitis virus and enterovirus 71, demonstrating the antiviral efficacy of this RNA ligand.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, University of Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langereis</LastName><ForeName>Martijn A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, University of Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olagnier</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Vaccine and Gene Therapy Institute of Florida, Port Saint Lucie, Florida, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Vaccine and Gene Therapy Institute of Florida, Port Saint Lucie, Florida, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Winkel</LastName><ForeName>Roel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Essen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoll</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiscott</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Vaccine and Gene Therapy Institute of Florida, Port Saint Lucie, Florida, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Kuppeveld</LastName><ForeName>Frank J M</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, University of Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C551867">5'PPP-RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011122">Polyphosphates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018168">Receptors, Retinoic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>NU43IAG5BC</RegistryNumber><NameOfSubstance UI="C005692">triphosphoric acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053487" MajorTopicYN="N">DEAD-box RNA Helicases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009690" MajorTopicYN="N">Nucleic Acid Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010849" MajorTopicYN="N">Picornaviridae</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011122" MajorTopicYN="N">Polyphosphates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012327" MajorTopicYN="N">RNA Virus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018168" MajorTopicYN="N">Receptors, Retinoic Acid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>4</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24759703</ArticleId><ArticleId IdType="pmc">PMC3997492</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0095927</ArticleId><ArticleId IdType="pii">PONE-D-13-54320</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kato H, Takahasi K, Fujita T (2011) RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunol Rev 243: 91&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">21884169</ArticleId></ArticleIdList></Reference><Reference><Citation>Goubau D, Deddouche S, Reis E Sousa C (2013) Cytosolic sensing of viruses. Immunity 38: 855&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111113</ArticleId><ArticleId IdType="pubmed">23706667</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlee M (2013) Master sensors of pathogenic RNA - RIG-I like receptors. Immunobiology 218: 1322&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114584</ArticleId><ArticleId IdType="pubmed">23896194</ArticleId></ArticleIdList></Reference><Reference><Citation>Stackaruk ML, Lee AJ, Ashkar AA (2013) Type I interferon regulation of natural killer cell function in primary and secondary infections. Expert Rev Vaccines 12: 875&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">23984959</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-L, Chen T-T, Pai L-M, Wesoly J, Bluyssen HAR, et al. (2013) A type I IFN-Flt3 ligand axis augments plasmacytoid dendritic cell development from common lymphoid progenitors. J Exp Med 210: 2515&#x2013;2522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832917</ArticleId><ArticleId IdType="pubmed">24145513</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploss A, Dubuisson J (2012) New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut 61 Suppl 1i25&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">22504917</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogan UB, Golge N, Akin MS (2013) The comparison of the efficacy of pegylated interferon &#x3b1;-2a and &#x3b1;-2b in chronic hepatitis B patients. Eur J Gastroenterol Hepatol 25: 1312&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pubmed">23652913</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleijfer S, Bannink M, Van Gool AR, Kruit WHJ, Stoter G (2005) Side effects of interferon-alpha therapy. Pharm World Sci 27: 423&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">16341948</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T, Wu X, Song D, Fang M, Guo S, et al. (2012) Effect of prophylactically applied CpG ODN on the development of myocarditis in mice infected with Coxsackievirus B3. Int Immunopharmacol 14: 665&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">23063973</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaskill JL, Marsh GA, Monaghan P, Wang L-F, Doran T, et al. (2013) Potent inhibition of Hendra virus infection via RNA interference and poly I:C immune activation. PLoS One 8: e64360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653894</ArticleId><ArticleId IdType="pubmed">23691205</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Pulido M, Borrego B, Sobrino F, S&#xe1;iz M (2011) RNA structural domains in noncoding regions of the foot-and-mouth disease virus genome trigger innate immunity in porcine cells and mice. J Virol 85: 6492&#x2013;6501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126542</ArticleId><ArticleId IdType="pubmed">21525336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Gil L, Goff PH, Hai R, Garc&#xed;a-Sastre A, Shaw ML, et al. (2013) A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol 87: 1290&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554167</ArticleId><ArticleId IdType="pubmed">23175362</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulet M-L, Olagnier D, Xu Z, Paz S, Belgnaoui SM, et al. (2013) Systems Analysis of a RIG-I Agonist Inducing Broad Spectrum Inhibition of Virus Infectivity. PLoS Pathog 9: e1003298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635991</ArticleId><ArticleId IdType="pubmed">23633948</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, et al. (2009) Recognition of 5&#x2032; triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 31: 25&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824854</ArticleId><ArticleId IdType="pubmed">19576794</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder M, Eberle F, Seitz S, M&#xfc;cke N, H&#xfc;ber CM, et al. (2011) Molecular mechanism of signal perception and integration by the innate immune sensor retinoic acid-inducible gene-I (RIG-I). J Biol Chem 286: 27278&#x2013;27287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149321</ArticleId><ArticleId IdType="pubmed">21659521</ArticleId></ArticleIdList></Reference><Reference><Citation>Samanta M, Iwakiri D, Kanda T, Imaizumi T, Takada K (2006) EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J 25: 4207&#x2013;4214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1570431</ArticleId><ArticleId IdType="pubmed">16946700</ArticleId></ArticleIdList></Reference><Reference><Citation>Plumet S, Herschke F, Bourhis J-M, Valentin H, Longhi S, et al. (2007) Cytosolic 5&#x2032;-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response. PLoS One 2: e279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1804102</ArticleId><ArticleId IdType="pubmed">17356690</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale Jr M (2008) Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454: 523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856441</ArticleId><ArticleId IdType="pubmed">18548002</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong HK, Cheong C, Choi BS (1996) Secondary structure of the panhandle RNA of influenza virus A studied by NMR spectroscopy. Nucleic Acids Res 24: 4197&#x2013;4201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC146218</ArticleId><ArticleId IdType="pubmed">8932372</ArticleId></ArticleIdList></Reference><Reference><Citation>Glickman JN, Howe JG, Steitz JA (1988) Structural analyses of EBER1 and EBER2 ribonucleoprotein particles present in Epstein-Barr virus-infected cells. J Virol 62: 902&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC253649</ArticleId><ArticleId IdType="pubmed">2828685</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, Hato S V, Langereis MA, Zoll J, Virgen-Slane R, et al. (2012) MDA5 detects the double-stranded RNA replicative form in picornavirus-infected cells. Cell Rep 2: 1187&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103987</ArticleId><ArticleId IdType="pubmed">23142662</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimmer E, Hellen CU, Cao X (1993) Genetics of poliovirus. Annu Rev Genet 27: 353&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">8122908</ArticleId></ArticleIdList></Reference><Reference><Citation>Witwer C, Rauscher S, Hofacker IL, Stadler PF (2001) Conserved RNA secondary structures in Picornaviridae genomes. Nucleic Acids Res 29: 5079&#x2013;5089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC97546</ArticleId><ArticleId IdType="pubmed">11812840</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, et al. (2009) 5&#x2032;-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci U S A 106: 12067&#x2013;12072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705279</ArticleId><ArticleId IdType="pubmed">19574455</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornung V, Ellegast J, Kim S, Brz&#xf3;zka K, Jung A, et al. (2006) 5&#x2032;-Triphosphate RNA is the ligand for RIG-I. Science 314: 994&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">17038590</ArticleId></ArticleIdList></Reference><Reference><Citation>Klump WM, Bergmann I, M&#xfc;ller BC, Ameis D, Kandolf R (1990) Complete nucleotide sequence of infectious Coxsackievirus B3 cDNA: two initial 5&#x2032; uridine residues are regained during plus-strand RNA synthesis. J Virol 64: 1573&#x2013;1583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC249292</ArticleId><ArticleId IdType="pubmed">2157045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, et al. (2005) Cell type-specific involvement of RIG-I in antiviral response. Immunity 23: 19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16039576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar H, Kawai T, Kato H, Sato S, Takahashi K, et al. (2006) Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med 203: 1795&#x2013;1803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2118350</ArticleId><ArticleId IdType="pubmed">16785313</ArticleId></ArticleIdList></Reference><Reference><Citation>Olagnier D, Scholte FEM, Chiang C, Albulescu IC, Nichols C, et al. (2014) Inhibition of dengue and chikungunya virus infection by RIG-I-mediated type I IFN-independent stimulation of the innate antiviral response. J Virol 88: 4180&#x2013;4194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3993760</ArticleId><ArticleId IdType="pubmed">24478443</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>